Beta Drugs Ltd

- Rahul Batra mentioned expecting a few conversions/orders in January and February which can help surpass the Rs. 230 crore revenue figure for the full year. - The company currently has clear orders from some good clients in the CRAMs (contract manufacturing) division. - Agreements for these clients are expected to be finalized by December, with commercial production starting by January or February. - The CRAMs business has added 3 to 4 new customers this year and plans to add another 3 to 4 in the next year. - No specific numeric value of the current order book or pending orders was disclosed, but the tone indicates a healthy pipeline with expected growth.

- There is no explicit mention of any current or future fundraising through debt or equity in the provided transcript. - The company discusses internal CAPEX investments, such as Rs. 8.8 crores spent in H1 FY23 mainly for capacity expansion and upgradation, without indicating external fundraising. - Rahul Batra mentions no major CAPEX requirements for the next 2-3 years until turnover reaches Rs. 400-450 crores, suggesting reliance on internal accruals. - The company is focusing on growth via expanding exports, CRAMs, and a new Cosmetics/Dermatology division without reference to raising external funds. - No direct references to plans for debt or equity issuance were made during the call.

- Beta Drugs has invested around Rs. 4 to 5 crores in scaling up a new API production line, focusing on exports, especially regulated markets (Page 4). - In April 2022, installed a large Lyophilizer increasing injectable capacity threefold; invested Rs. 1.5 crores on this and Rs. 2.5 crores on upgrading injectable facilities including HVAC system and filter validations (Page 13). - Rs. 8.8 crores CAPEX incurred in H1 FY23 mainly on Lyophilizer and injectable facility upgrades (Page 13). - New API production line machinery installation planned to commence by December 2022 (Page 4, 13). - Land acquired for setting up a new plant for Dermatology and Cosmetology division, with plans to build own manufacturing plant in next 2-3 years (Pages 5, 6). - No major CAPEX expected for next 2-3 years till turnover reaches Rs. 400-450 crores, leveraging existing capacities (Page 13).

- Beta Drugs expects to achieve around Rs. 230 crores revenue for the full year, with potential to surpass this after product conversions in January-February (Page 17). - Company targets 25% to 30% growth annually over the next 3-4 years, driven primarily by oncology portfolio and export markets like LATAM, African, Asian, and CIS regions (Pages 11, 13). - Exports, especially formulation exports, are major growth drivers; plans to file over 200 dossiers in 2-3 years and expand market presence in regulated and semi-regulated markets (Page 4). - Cosmetic-Dermatology division aims for Rs. 30-35 crores topline in 3 years, with plans to build a strong brand and own manufacturing plant in 2-3 years (Pages 5, 16). - CRAMs (contract manufacturing) business is steadily growing with 28-30 customers and addition of new clients expected, contributing progressively to revenues (Pages 16, 17).

- Beta Drugs expects revenue growth of 25% to 30% over the next 3-4 years, driven primarily by oncology portfolio and export expansion into LATAM, African, Asian, and CIS markets. - EBITDA margins for oncology currently exceed 30-35%, with derma/cosmetology segment target margins conservatively at 15-17%, expected to improve to oncology levels once own production commences in 2-3 years. - Gross margins improved from 37% (H1 last year) to ~42% this year; material cost as percentage of sales reduced from 73% to 68%. - Receivable days steady around 90-96 days, indicating stable cash cycle. - Operating cash flow dipped in H1 FY23 due to CAPEX creditor payments but overall financials remain strong. - CAPEX focus on injectable facility upgrades and new API line to support margin expansion and volume growth. - Management confident in sustaining strong earnings growth and profitability aligned with revenue trajectory and margin expansion plans.